Skip to content

Oncology
GI Oncology
Breast Cancer
Lung Cancer
GI Cancer
Podcasts

Search for:

Oncology
GI Oncology
Breast Cancer
Lung Cancer
GI Cancer
Podcasts

Prostate Cancer

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

mHSPC / mCSPC, Prostate Cancer / OncologyNexus Team

FDA approves darolutamide (Nubeqa) for mCSPC: 46% reduction in disease progression risk vs placebo in ARANOTE trial.

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer Read More »

How Low Do You Need to Go? Association Between Various PSA Response Measures and Clinical Outcomes in mCSPC in the Veteran Health Administration (VHA) Data

mHSPC / mCSPC / OncologyNexus Team

PSA nadir <0.2 ng/mL within 9 months shows 54% lower death risk vs 22% for ≥90% decline in mCSPC veterans receiving ADT-based therapy.

How Low Do You Need to Go? Association Between Various PSA Response Measures and Clinical Outcomes in mCSPC in the Veteran Health Administration (VHA) Data Read More »

Search

Categories

Advanced RCC (2)
Bladder Cancer (7)
Breast Cancer (1)
Colorectal Cancer (1)
Diagnostics (1)
Diffuse Midline Glioma (1)
DLBCL (1)
Endometrial Cancer (1)
Genitourinary Oncology (1)
Head & Neck Squamous Cell Carcinoma (HNSCC) (1)
Health Insurance (1)
Health Policy & Access (1)
Healthcare Economics (1)
Hepatocellular Carcinoma (1)
HER2+ (2)
Hormone Receptor Positive (HR+) (1)
Melanoma (1)
mHSPC / mCSPC (2)
Multiple Myeloma (MM) (1)
Muscle Invasive (MIBC) (1)
Non-Muscle Invasive (NMIBC) (5)
Non-Small Cell Lung Cancer (NSCLC) (3)
Practice Efficiency (1)
Prostate Cancer (1)
Renal Cell Carcinoma (1)
Upper GI/Gastroesophageal Cancer (1)

Subscribe

Email

The form has been submitted successfully!

There has been some error while submitting the form. Please verify all form fields again.

Recent Post

Immune Checkpoint Inhibitors and Survival Disparities by Health Insurance Coverage Among Patients with Metastatic Cancer
Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?
FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer
T-DXd Plus Pertuzumab Outperforms Standard of Care for First-Line Treatment of Advanced HER2-Positive Breast Cancer
RedirecTT-1 Trial: Talquetamab + Teclistamab for Multiple Myeloma with Extramedullary Disease

Sign up for Newsletter

Maecenas potenti ultrices, turpis eget turpis gravida.

There was an error trying to submit your form. Please try again.

This field is required.

There was an error trying to submit your form. Please try again.

Company

About
Contact
Our Staff
Advertise

Copyright © 2025 oncologynexus.com.